
Alnylam Unveils “Alnylam 2030” Growth Strategy
Alnylam Pharmaceuticals, Inc., the global leader in RNA interference (RNAi) therapeutics, has announced the launch of its new five-year corporate strategy, “Alnylam 2030,” outlining an ambitious roadmap to scale operations, strengthen leadership in transthyretin (ATTR) amyloidosis, advance a diversified pipeline…








